Press releases
- Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer
- Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials
- Guardant Health Named to TIME100 Most Influential Companies
- Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening
- FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option
- Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening
- Guardant Health to Participate in Upcoming Investor Conferences
- Guardant Health Receives EU IVDR Certification for Guardant360® CDx Liquid Biopsy for Tumor Mutation Profiling Across All Solid Cancers and Companion Diagnostic Indications
- Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Guardant Health to present real-world data supporting performance of Shield™ blood test for colorectal cancer screening at 2024 Digestive Disease Week
More ▼
Key statistics
On Friday, Guardant Health (GH*:MEX) closed at 416.60, 41.78% above the 52 week low of 293.83 set on Mar 26, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | 547.67 |
Previous close | 547.67 |
Average volume | 0.00 |
---|---|
Shares outstanding | 122.37m |
Free float | 116.82m |
P/E (TTM) | -- |
Market cap | 3.43bn USD |
EPS (TTM) | -3.92 USD |
Data delayed at least 20 minutes, as of May 03 2024 12:30 BST.
More ▼